Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
The Lancet ( IF 98.4 ) Pub Date : 2018-01-01 , DOI: 10.1016/s2213-8587(17)30359-5 Aneliya Parvanova , Matias Trillini , Manuel A Podestà , Ilian Petrov Iliev , Barbara Ruggiero , Manuela Abbate , Annalisa Perna , Francesco Peraro , Olimpia Diadei , Nadia Rubis , Flavio Gaspari , Fabiola Carrara , Nadia Stucchi , Antonio Belviso , Antonio C Bossi , Roberto Trevisan , Giuseppe Remuzzi , Martin de Borst , Piero Ruggenenti , Norberto Perico , Piero Ruggenenti , Giuseppe Remuzzi , Stefano Rota , Matias Trillini , Barbara Ruggiero , Maria Carolina Aparicio , Silvia Prandini , Daniela Cugini , Giulia Gherardi , Manuel A Podestà , Roberto Trevisan , Anna Corsi , Antonio C. Bossi , Aneliya Parvanova , Ilian Petrov Iliev , S Yakymchuk , Veruscka Lecchi , Antonio Belviso , Ruggero Mangili , Nadia Rubis , Wally Calini , Olimpia Diadei , Bogdan Ene-Iordache , Sergio Carminati , Davide Martinetti , Giovanni Antonio Giuliano , Annalisa Perna , Francesco Peraro , Angela Russo , Flavio Gaspari , Fabiola Carrara , Silvia Ferrari , Nadia Stucchi , Antonio Nicola Cannata , Paola Boccardo , Sara Peracchi , Martin De Borst , Serena Bettoni , Irene Cattaneo , Davide Franchina , Haian Ha Phan , Grace Igiraneza , Tamas Kaucsár , Sergio Luis Lima , Meg Lunney , Huong Tran
The Lancet ( IF 98.4 ) Pub Date : 2018-01-01 , DOI: 10.1016/s2213-8587(17)30359-5 Aneliya Parvanova , Matias Trillini , Manuel A Podestà , Ilian Petrov Iliev , Barbara Ruggiero , Manuela Abbate , Annalisa Perna , Francesco Peraro , Olimpia Diadei , Nadia Rubis , Flavio Gaspari , Fabiola Carrara , Nadia Stucchi , Antonio Belviso , Antonio C Bossi , Roberto Trevisan , Giuseppe Remuzzi , Martin de Borst , Piero Ruggenenti , Norberto Perico , Piero Ruggenenti , Giuseppe Remuzzi , Stefano Rota , Matias Trillini , Barbara Ruggiero , Maria Carolina Aparicio , Silvia Prandini , Daniela Cugini , Giulia Gherardi , Manuel A Podestà , Roberto Trevisan , Anna Corsi , Antonio C. Bossi , Aneliya Parvanova , Ilian Petrov Iliev , S Yakymchuk , Veruscka Lecchi , Antonio Belviso , Ruggero Mangili , Nadia Rubis , Wally Calini , Olimpia Diadei , Bogdan Ene-Iordache , Sergio Carminati , Davide Martinetti , Giovanni Antonio Giuliano , Annalisa Perna , Francesco Peraro , Angela Russo , Flavio Gaspari , Fabiola Carrara , Silvia Ferrari , Nadia Stucchi , Antonio Nicola Cannata , Paola Boccardo , Sara Peracchi , Martin De Borst , Serena Bettoni , Irene Cattaneo , Davide Franchina , Haian Ha Phan , Grace Igiraneza , Tamas Kaucsár , Sergio Luis Lima , Meg Lunney , Huong Tran
|
Macroalbuminuria predicts renal and cardiovascular events in patients with type 2 diabetes. We aimed to assess the albuminuria-lowering effects of salt restriction, paricalcitol therapy, or both, in this population.
中文翻译：
在2型糖尿病和氯沙坦耐药的大白蛋白尿患者中，有或没有使用帕罗西醇的中度盐分限制（继续）：一项随机，双盲，安慰剂对照，交叉试验。
巨蛋白尿可预测2型糖尿病患者的肾脏和心血管事件。我们旨在评估该人群中限盐，pariccitol治疗或两者的降低白蛋白尿的作用。
更新日期：2017-12-20
中文翻译：
在2型糖尿病和氯沙坦耐药的大白蛋白尿患者中，有或没有使用帕罗西醇的中度盐分限制（继续）：一项随机，双盲，安慰剂对照，交叉试验。
巨蛋白尿可预测2型糖尿病患者的肾脏和心血管事件。我们旨在评估该人群中限盐，pariccitol治疗或两者的降低白蛋白尿的作用。
京公网安备 11010802027423号